UMIN-CTR Clinical Trial

Recruitment status Enrolling by invitation
Unique ID issued by UMIN UMIN000027344
Receipt No. R000031236
Official scientific title of the study The safety and efficacy of etelcalcetide for the treatment of secondary hyperparathyroidism compared with cinacalcet
Date of disclosure of the study information 2017/05/15
Last modified on 2017/05/15 (Ver. 1)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Official scientific title of the study The safety and efficacy of etelcalcetide for the treatment of secondary hyperparathyroidism compared with cinacalcet
Title of the study (Brief title) The safety and efficacy of etelcalcetide compared with cinacalcet
Region
Japan

Condition
Condition Patients on maintenance hemodialysis treated with cinacalcet for secondary hyperparathyroidism
Classification by specialty
Nephrology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To evaluate the control of iPTH, Ca, P, the side effect, and the dosage of etelcalcetide when switching from cinacalcet to etelcalcetide
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes iPTH, Ca, P, side effect, dosage of etelcalcetide
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Self control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 etelcalcetide (5mg - 10mg) every hemodialysis session
6 months
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
85 years-old >=
Gender Male and Female
Key inclusion criteria Patients with secondary hyperparathyroidism who are undergoing maintenance hemodialysis
Key exclusion criteria Nothing
Target sample size 10

Research contact person
Name of lead principal investigator Takahiro Yajima
Organization Matsunami general hospital
Division name Department of nephrology
Address 185-1, dendai, Kasamatsu-chou, Hashima-gun, Gifu
TEL 058-388-0111
Email yajima5639@gmail.com

Public contact
Name of contact person Takahiro Yajima
Organization Matsunami general hospital
Division name Department of nephrology
Address 185-1, dendai, Kasamatsu-chou, Hashima-gun, Gifu
TEL 058-388-0111
Homepage URL
Email yajima5639@gmail.com

Sponsor
Institute Matsunami general hospital
Institute
Department

Funding Source
Organization Matsunami general hospital
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2017 Year 05 Month 15 Day

Progress
Recruitment status Enrolling by invitation
Date of protocol fixation
2017 Year 05 Month 08 Day
Anticipated trial start date
2017 Year 05 Month 08 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Related information
URL releasing protocol
Publication of results Unpublished
URL releasing results
Results
Other related information

Management information
Registered date
2017 Year 05 Month 15 Day
Last modified on
2017 Year 05 Month 15 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031236